Our extensive Hatch-Waxman litigation practice and successful practice in post-grant PTO proceedings, combined with our deep technical expertise in biotechnology, uniquely positions us to develop and implement effective IP strategies for biosimilars. This industry-specific expertise is backed by one of the largest and most experienced biotechnology groups in IP law, with more than 75 attorneys and scientists representing clients in all stages of their business and technology development, as well a talented litigation group adept in all aspects of biotechnology IP law.

Our attorneys have the bench strength to help you successfully navigate the biosimilars pathway.

Up-to-date knowledge of biosimilars legislation

IP litigators with numerous trial and appellate successes

Extensive Hatch-Waxman litigation experience

Successful Post-Grant PTO practice on behalf of patent owners and petitioners

Over 20 attorneys with PhD’s in the life sciences

Extensive experience in biologics patent prosecution

Licensing and other transactional experience related to biologics

Count on our deep expertise across a spectrum of technologies.

Antibodies & Immunology



Research Tools & Reagents


Biological Manufacturing of Chemicals

Diagnostic Tools

Personalized Medicine

Stem Cells & Regenerative Medicine


Representative Engagements

Australia National University

California Institute of Technology


Chrontech Pharma

Creative Peptides Sweden AB

Cytori Therapeutics

Eppendorf AG

Harvard University

Healthgen Biotechnology, Inc. in Wuhan

Hitachi Chemical Research Center


Imagine AB

ISIS Pharmaceuticals

Kyoto University

The National Institutes of Health

Stanford University

The University of California (UCSD, UCI, UCLA, UCSF)

IRVINE, Calif., April 9, 2024 – Knobbe Martens is proud to announce that partners Susan Natland and Sheila Swaroop have been shortlisted by Managing IP in the 2024 Women in Business Law Awards. Ms...
IRVINE, Calif., March 28, 2024 – Knobbe Martens is proud to announce that the firm and several of its professionals have achieved outstanding rankings in the 2024 Patexia Patent Prosecution...
Safe Harbor Defense Under 35 U.S.C. §271(e)(1) Requires That the Accused Activity Is Solely for Uses Reasonably Related to Submitting Information to the FDA